Literature DB >> 7752092

Dapsone-induced hemolytic anemia: role of glucose-6-phosphate dehydrogenase in the hemolytic response of rat erythrocytes to N-hydroxydapsone.

S Grossman1, R Budinsky, D Jollow.   

Abstract

Individuals deficient in erythrocytic glucose-6-phosphate dehydrogenase (G6PD) show about a 2-fold increase in sensitivity toward dapsone-induced hemolytic anemia. Rat studies have shown that the hemolytic activity of dapsone resides in its N-hydroxy metabolites; exposure of rat red cells to N-hydroxy-dapsone in vitro followed by readministration to isologous rats results in premature splenic sequestration of the damaged cells. This study examines the ability of the steroid, epiandrosterone, to inhibit rat red cell G6PD and the effect of such inhibition on the susceptibility of rat red cells to N-hydroxydapsone hemolytic activity. Epiandrosterone was found to inhibit rat red cell G6PD uncompetitively and to suppress red cell hexose monophosphate shunt activity by more than 95%. Epiandrosterone suppression of rat red cell G6PD activity resulted in about a 2-fold increase in sensitivity of the rat cells to N-hydroxydapsone hemolytic activity, and a modest but significant increase in depletion of red cell glutathione. In contrast, suppression of rat red cell catalase activity by aminotriazole had no effect on the hemotoxicity of N-hydroxydapsone. Epiandrosterone appears to be a useful tool to explore the mechanism by which G6PD deficiency enhances susceptibility to hemolytic drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7752092

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Dapsone hydroxylamine induces premature removal of human erythrocytes by membrane reorganization and antibody binding.

Authors:  Luciana Bordin; Cristina Fiore; Francesco Zen; Michael D Coleman; Eugenio Ragazzi; Giulio Clari
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  Advances in the Pharmacogenomics of Adverse Drug Reactions.

Authors:  Susannah L Collins; Daniel F Carr; Munir Pirmohamed
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

Review 3.  Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review.

Authors:  Ilan Youngster; Lidia Arcavi; Renata Schechmaster; Yulia Akayzen; Hen Popliski; Janna Shimonov; Svetlana Beig; Matitiahu Berkovitch
Journal:  Drug Saf       Date:  2010-09-01       Impact factor: 5.228

Review 4.  The medication for pneumocystis pneumonia with glucose-6-phosphate dehydrogenase deficiency patients.

Authors:  Ziyu Zhang; Qinhui Li; Xiaoyan Shen; Lankai Liao; Xia Wang; Min Song; Xi Zheng; Yulian Zhu; Yong Yang
Journal:  Front Pharmacol       Date:  2022-09-07       Impact factor: 5.988

5.  In Vitro Protective Effect and Antioxidant Mechanism of Resveratrol Induced by Dapsone Hydroxylamine in Human Cells.

Authors:  Rosyana V Albuquerque; Nívea S Malcher; Lílian L Amado; Michael D Coleman; Danielle C Dos Santos; Rosivaldo Sa Borges; Sebastião Aldo S Valente; Vera C Valente; Marta Chagas Monteiro
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

6.  Adverse reactions in leprosy patients who underwent dapsone multidrug therapy: a retrospective study.

Authors:  Sanjeev Guragain; Namrata Upadhayay; Bishwa Mohan Bhattarai
Journal:  Clin Pharmacol       Date:  2017-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.